Alvotech
ALVO US
ALVO USAlvotech
United States CompositeCompany Description
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Address
- 9, Rue de Bitbourg Luxembourg Luxembourg 1273
- Website
- www.alvotech.com
- Business
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Company News
AbbVie stock slides 6% amid concerns about falling Humira sales
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
Analysts Are Bullish on These Healthcare Stocks: Alvotech (ALVO), Cardinal Health (CAH)
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Alvotech (ALVO) and Pacific Biosciences (PACB)
J&J beats first-quarter profit estimates on cancer drugs strength
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Alvotech Announces Increase in Number of Own Shares
Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long
Analysts’ Top Healthcare Picks: Healthequity (HQY), Exscientia Plc (EXAI)
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET